Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities 3 year CAGR for the year ending December 31, 2023: -9.70%

Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities 3 year CAGR is -9.70% for the year ending December 31, 2023, a -122.25% change year over year. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2022 was -6.61, a -17.94% change year over year.
  • Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2021 was -5.61, a 17.03% change year over year.
  • Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2020 was -6.76, a -202.50% change year over year.
  • Day One Biopharmaceuticals Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2019 was -2.23.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email